Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice

AIMS/HYPOTHESIS: IL-2 injections are a promising therapy for autoimmune type 1 diabetes but the short half-life of this cytokine in vivo limits effective tissue exposure and necessitates frequent injections. Here we have investigated whether an injectable hydrogel could be used to promote prolonged...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetologia
Autors principals: Nagy, Nadine, Kaber, Gernot, Kratochvil, Michael J., Kuipers, Hedwich F., Ruppert, Shannon M., Yadava, Koshika, Yang, Jason, Heilshorn, Sarah C., Long, S. Alice, Pugliese, Alberto, Bollyky, Paul L.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7720893/
https://ncbi.nlm.nih.gov/pubmed/33125521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-020-05314-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars